Survivin Antibody

Survivin (BIRC5 or IAP4) is the smallest member of the inhibitor of apoptosis (IAP) proteins, containing only a single baculovirus IAP repeat (BIR) domain and lacking the C-terminal RING domain. Survivin has a theoretical molecular weight of 16.5 kDa (wild-type protein) and exists as ten splice variant forms including the most predominant isoforms, survivin-2B and surviving-DeltaEx3 (1). It also undergoes phosphorylation by PKA, Plk1, Cdk1, CKII and Aurora B at multiple sites (e.g. Serine 20 and Threonine 34, 53 and 117).

Besides being highly abundant in fetal development and expressed in proliferating adult cells such as activated T lymphocytes, erythroblasts, and self-renewing stem cells, survivin is generally absent in adult tissues. However, it is elevated in common cancers such as lung, colon, pancreas, breast and prostate where it drives proliferation, metastasis, poor prognosis, and decreased patient survival (2).

Survivin has been shown to be involved in multiple cellular processes including cell cycle progression, mitotic spindle assembly, kinetochore attachment, angiogenesis, migration, and its anti-apoptotic activity has been linked to both its monomeric and homodimeric forms. Survivin impacts the function of other IAP members, c-IAP1 and c-IAP-2, or modulates the inhibitory activity of XIAP against caspases by forming a stable complex with XIAP and HBXIP. During the intrinsic apoptotic pathway, survivin may prevent the release of mitochondrial APAF1 into the cytoplasm or hinder the association of SMAC with other IAPS, which results in prolonged cell survival (3).

References

1. Sah NK, Seniya C. (2015) Survivin splice variants and their diagnostic significance. Tumour Biol. 36(9):6623-31. PMID: 26245993

2. Lladser A, Sanhueza C, Kiessling R, Quest AF. (2011) Is survivin the potential Achilles' heel of cancer? Adv Cancer Res. 111:1-37. PMID: 21704829

3. Wheatley SP, Altieri DC. (2019) Survivin at a glance. J Cell Sci. 132(7). PMID: 30948431

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Rat.

We have publications tested in 2 applications: IF/IHC, IHC-P.

Showing Publications 1 - 4 of 4.

Publications using NB100-56168	Applications	Species
Mehra R, Yang D, Handorf E et al. Analysis of a protein expression biomarkers in HPV negative SCCHN. Cancer Research: Abstract from AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. 2014-01-01 (IHC-P, Human) Details: Survivin antibody used for IHC-P on human papillomavirus negative (HPV) (-) squamous cell head and neck cancer (SCCHN) tissue microarrays.	IHC-P	Human
Khan SA, Burke M, Zhu F et al. Survivin expression and impact on head and neck cancer outcomes Oral Oncol 2020-11-19 [PMID: 33221541] (IF/IHC, Human)	IF/IHC	Human
Taniai E, Hayashi H, Yafune A et al. Cellular distribution of cell cycle-related molecules in the renal tubules of rats treated with renal carcinogens for 28 days: relationship between cell cycle aberration and carcinogenesis Arch Toxicol 2012-03-13 [PMID: 22411273] (IF/IHC, Rat)	IF/IHC	Rat
Taniai Eriko, Hayashi Hitomi, Yafune Atsunori et al. Cellular distribution of cell cycle-related molecules in the renal tubules of rats treated with renal carcinogens for 28 days: relationship between cell cycle aberration and carcinogenesis. Arch Toxicol. 2012-09-01 [PMID: 22411272] (Rat)		Rat

Array NB100-56168

• Survivin Antibodies
• Survivin Antibody Pack
• Survivin Lysate
• Survivin Proteins
• Survivin ELISAs
• Survivin Proteins and Enzyme